Treatment and Follow Up for HSIL of the Vulva and Differentiated VIN

#### E.J. Mayeaux, Jr., M.D., DABFP, DABPM, FAAFP

Professor and Chairman USC Department of Family and Preventive Medicine Professor of Obstetrics and Gynecology University of South Carolina School of Medicine Columbia, SC

Nod to Cynthia Rasmussen, MD







- No financial relationships or conflict of interest to disclose
- We will discuss off-label use of topical imiquimod for HSIL





#### **Objectives:**

# HSIL and dVIN are different!

Treatment alternatives for both

Post Treatment Surveillance Protocols



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

## Evolving 2015 Terminology (now c/w LAST and WHO)

#### LSIL of the Vulva

• Vulvar LSIL, flat condyloma, or HPV effect

#### **HSIL of the Vulva**


- Vulvar HSIL, VIN usual type (warty, basaloid, mixed)
- Associated with carcinogenic HPV types

#### **Differentiated VIN**

- Associated with vulvar dermatoses
- Not associated with HPV

Bornstein J, et al. J Lower Gen Tract Dis 2016;20:11-14.





SCC Incidence / 100,000

van de Nieuwenhof et al. Eur J CA 2009;851-56


#### AS € P

Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases ASCCP2018 Annual Meeting

20

10


0







Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

## HSIL Clinical Behavior





Preti M, et al. Best Practice & Research Clinical Obstetrics and Gynaecology 2014; 24:1052-62




#### Lee A, et al. JAMA Dermatol 2015;151:1061-7



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

# Incidence Rate of Neoplasias in Women With and Without a History of CIN3



Ebisch RMF, et al. J Clin Oncol. 2017 May 25. Epub]



Incidence Rate (per 100,000

oerson-years)

Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases



## Visual Inspection

## Biopsy





Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases 

## **Colposcopic Techniques**

- 3% to 5% acetic acid
- Soak initially for 3-5 min.
- Use copious amounts
- Reapply often
- Avoid using in presence of breaks in epithelium or inflammation






#### White HSIL

## **Gray-Brown HSIL**



## Red HSIL



### Vin Differentiated




Courtesy of Hope Haefner, MD




Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

## **Differentiated VIN**



A AN AN

## **Punch Biopsy**



#### • Anesthesia

- 1% lidocaine (sodium bicarb)
- 27-30 gauge needle to inject 1-3 cc's of anesthetic agent
- Inject intradermally
- 3-5 mm Keyes punch
- Fine suture (3.0 or 4.0)
  - Hemostasis &  $\downarrow$  pain
  - Monsel's/Silver nitrate slows healing

#### AS & P

Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

#### **Baby Tischler**



Courtesy Dr. E.J. Mayeaux, Jr.



Cervical biopsy

instruments

that can also

vulvar biopsy

be used for



## ICD-10 and CPT Codes

Code Descriptor D39.8 Neoplasm of uncertain behavior of other specified female genital organs N90.0 Mild vulvar dysplasia (VIN1/LSIL) N90.1 Moderate vulvar dysplasia (VIN2/HSIL) D07.1 Carcinoma in situ of vulva (VIN3/HSIL) C51.- Malignant neoplasm of vulva Malignant neoplasm of labium majus C51.0 Malignant neoplasm of labium minus C51.1 C51.2 Malignant neoplasm of clitoris Malignant neoplasm of overlapping sites of vulva C51.8 C51.9 Malignant neoplasm of vulva, unspecified

CPT 56605 - Biopsy of vulva or perineum (separate procedure); 1 lesion

CPT 56606 (biopsy of vulva or perineum; each separate additional lesion



### Treatment for Differentiated VIN


# Wide Local Excision





Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

#### dVIN - Unexpected stromal invasion found 3.2-18.8% of the time



Chafe W, et al. Gynecol Oncol. 1988;31:154-65. van Seters M, et al. Bynecol Oncol. 2005;97:645-51.



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

#### **Treatment of HSIL: Surgical**



Ribeiro F, et al. J Low Genit Tract Dis. 2012 Jul;16(3):313-7.



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases



Courtesy Dr. E.J. Mayeaux, J



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

## Laser Treatment of HSIL

Courtesy Dr. Elsa Diaz, MD

## Margins and Depth Vulvar HSIL

- Margins
- Depth
  - Hair bearing areas to 2.7 mm
  - Non-hair bearing = 0.1 to 1.9 mm (average = 0.5 +/- 0.2 mm)

Committee on Gynecologic Practice of American College Obstetricians and Gynecologists. ACOG Committee Opinion No. 509: Management of vulvar intraepithelial neoplasia. Obstet Gynecol. 2011 Nov;118(5):1192-4.



## Medical Treatment for HSIL

#### Imiguimod 5%

- Two to three times weekly for 12-16 weeks
- Colpo every 4-6 weeks during treatment Excision for failures
- Pain and erythema may limit use

#### **Cidofovir 1%**

- Response similar to Imiquimod in 2016 Cochrane review
- Hair bearing skin unresponsive. Tends to ulcerate

#### **Photodynamic Therapy**


- ALA sensitizer + light = cell death
- Quality of evidence "poor" in 2016 Cochrane review

Lawrie TA, et al. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No: CD011837.



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

#### Recurs After Treatment (mean follow-up 39 months)



Gynecologic Oncology. 2005; 97: 645-651

**ASCCP**2018 Annual Meeting



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

#### Risk of Recurrent Disease with HSIL and dVIN: 9%-50%

Positive MarginsMultiple lesionsRisk of cancer remains throughoutlifetime

Surgical treatment



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

#### **Post-Treatment Surveillance Regimens**

Follow at 6 and 12 months, then yearly thereafter

• ASCCP Committee Opinion # 675, October 2016

Follow Q 6 months X 5 years, then yearly

 Satmary W, et al. Gynecol Oncol (2017), https://doi.org/10.1016/j.ygyno.2017.10.029

Follow Q 3 months for 2-3 years, then Q 6 months

• Best Practice and Research Clinical ObGyn 2014; 28: 1051-1062



#### Vaccinate for HPV

## Treat Lichen Sclerosus and Lichen Planus

#### Prevention

## **Smoking Cessation**

#### **Biopsy**



Improving Lives Through the Prevention & Treatment of Anogenital & HPV-Related Diseases

## References

- 1. Management of Vulvar Intraepithelial Neoplasia. Committee Opinion number 675. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016; 128 (4): e178-182.
- 2. Satmary W et al, Vulvar intraepithelial neoplasia: Risk factors for recurrence. Gynecol Oncol (2017), https://doi.org/10.1016/j.ygyno.2017.10.029
- 3. Preti M et al. Vulvar intraepithelial neoplasia. Best Practice & Research Clinical Obstetrics and Gynaecology 28 (2014)1051-1062.
- 4. Kaushik S, et al. Surgical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Databaseof Systematic Reviews 2014, Issue 3. Art. No: CD007928. DOI: K10.1002/14651858. CD007928.pub3.
- 5. Pepas L, et al. Medical interventions for high-grade vulval intraepithelial neoplasia. Cochrane Databaseof Systematic Reviews 2015, Issue 8, Art. No.:CD007924.
- 6. Lawrie TA, et al. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database of Systematic Reviews 2016, Issue 1. Art. No: CD011837.
- 7. Bornstein J, et al, for the ISSVD Terminology Committee. The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions. J Lower Gen Tract Dis 2016;20:11-14.
- 8. Bigby S et al. The Natural History of Vulvar Intraepithelial Neoplasia, Differentiated Type: Evidence for Progression and Diagnostic Challenges. Intl J Gynecol Path 2016; 35:574-584.
- 9. Chokoeva A, et al. Vulvar Cancer: a review for dermatologists. Wein Med Wochenschr 2015;165:164.

